Anxious investors who picked April to go on a long internet-free vacation couldn't have planned it better. Earlier this month, the S&P 500 index quickly sank more than 10% after President Donald Trump unveiled tariff rules that threatened the U.S. economy.

PayPal stock price on Tuesday, when it publishes its first-quarter financial results, will show whether its business is growing or not. While the PYPL shares have bounced back in the past few days, they remain significantly lower than their 2024 highs.

There's no question that 2025 has been a rough year for AI stocks thus far.

Rivian (RIVN 4.42%) is expected to report earnings on May 6. So far this year, shares of the EV maker have been weak, falling by more than 10%.

Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgery in the U.S. presented as a late-breaker at the American Urologic Association annual meeting Company confirms Hugo RAS system submission to the U.S. Food and Drug Administration GALWAY, Ireland and LAS VEGAS , April 26, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced that the Expand URO Investigational Device Exemption (IDE) clinical study, the largest such study for robotic-assisted urologic surgery ever conducted, met both primary safety and effectiveness endpoints. The prospective, multi-center, single-arm IDE study included 137 patients who underwent …

Despite a ton of volatility, shares of Dutch Bros (BROS 2.99%) are still up 98% in the past 12 months (as of April 22). The up-and-coming coffeehouse chain is starting to win over investors who are interested in growth potential for their portfolios.

2025 has been a tough year for electric vehicle stocks. Companies like Lucid Group and Tesla have seen their valuations plummet.

Unlike the previous two years, 2025 hasn't been a great time to be an investor in technology stocks. As of this writing, each member of the "Magnificent Seven" is down at least 10% year to date.

Coca-Cola (KO -0.77%) is one of the most well-recognized companies on Earth. It operates on a global scale, and its namesake brand is the leader in the carbonated beverage niche of the broader beverage industry.

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 1

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 95 percent progression-free survival rate at 9-months signals the promise of TAR-200 in this high-risk patient population LAS VEGAS , April 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain types of bladder cancer. These first results show the promise of TAR-200 in this patient population with more than …

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR1

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR Results reinforce potential of TAR-200 to transform outcomes for certain types of BCG-unresponsive, high-risk non-muscle invasive bladder cancer LAS VEGAS , April 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from Cohort 2 of the pivotal Phase 2b SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain types of bladder cancer. The findings demonstrate the highest complete response rate without reinduction with more than half …

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a cli.

Saint Herblain (France), April 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France's national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva's single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV) following reports of serious adverse events (SAEs) in elderly people with comorbidities during the ongoing vaccination campaign in La Reunion and Mayotte. Valneva has been responding to the French government's call for vaccine supply of IXCHIQ® in La Reunion1 as the island is going through …

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In The Bancorp To Contact Him Directly To Discuss Their Options

TSMC (TSM), also known as Taiwan Semiconductor Manufacturing Company, is the subject of this week's tech sector deep dive! George Tsilis examines the global foundry leader's business operations and describes how TSMC became the industry standard for semiconductor manufacturing.

While Tesla (NASDAQ: TSLA) stock has reacted positively despite disappointing Q1 2025 earnings, part of Wall Street expects it to hold its current price over the next 12 months.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In TFI To Contact Him Directly To Discuss Their Options

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025, both dates inclusive (the “Class Period”), of the important May 19, 2025 lead plaintiff deadline.